3 -(methylsulfonyl)benzenesulfonamide | 22821-83-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3 -(methylsulfonyl)benzenesulfonamide
• 英文别名: 3-Methansulfonyl-benzolsulfonsaeureamid；3-Methanesulfonylbenzene-1-sulfonamide；3-methylsulfonylbenzenesulfonamide
• CAS: 22821-83-6
• 化学式: C₇H₉NO₄S₂
• mdl: MFCD11205186
• 分子量: 235.285
• InChiKey: YUFIQCIEPNCJQE-UHFFFAOYSA-N

物化性质

• 沸点：
  517.1±56.0 °C(Predicted)
• 密度：
  1.469±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3 -(methylsulfonyl)benzenesulfonamide 在 氢氧化钾 作用下， 反应 4.0h， 生成 N-[1-[2-(2-Guanidino-thiazol-4-ylmethylsulfanyl)-ethylamino]-meth-(Z)-ylidene]-3-methanesulfonyl-benzenesulfonamide; compound with (E)-but-2-enedioic acid
  参考文献：
  名称：

  Inhibitors of gastric acid secretion: N-sulphonyl formamidines in a series of new histamine H2-receptor antagonists

  摘要：

  DOI：

  10.1016/0223-5234(88)90174-2
• 作为产物：
  描述：

  3-甲砜基苯胺 在 盐酸 、 氨 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.33h， 生成 3 -(methylsulfonyl)benzenesulfonamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
  [FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À L'ACTIVITÉ D'UN NLRP

  摘要：

  在一个方面，公式A的化合物，或其药用可接受盐，被描述为（公式A）或其药用可接受盐，其中在公式A中显示的变量可以如本文中的任何地方所定义。

  公开号：

  WO2020086728A1

文献信息

• [EN] SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] SULFONAMIDES ET COMPOSITIONS ASSOCIÉES POUR LE TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE NLRP
  申请人：IFM TRE INC

  公开号：WO2019079119A1

  公开（公告）日：2019-04-25

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

  在一个方面，公式AA的化合物或其药用可接受的盐被描述：其中在公式AA中显示的变量可以如本文中的任何地方所定义。化合物AA是NLRP1和/或NLRP3的调节剂
• CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
  申请人：Ameriks Michael K.

  公开号：US20080200454A1

  公开（公告）日：2008-08-21

  Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

  描述了与碳相连的四氢吡唑吡啶化合物，这些化合物可作为cathepsin S调节剂。这些化合物可用于制备药物组合物和治疗疾病状态、疾病和病况的方法，这些疾病状态、疾病和病况是由cathepsin S活性介导的，如银屑病、疼痛、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
  申请人：Pfizer Inc

  公开号：US06433009B1

  公开（公告）日：2002-08-13

  A compound of the formula wherein R1 and R2 are as defined above, useful in the treatment and condition selected from the group consisting of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

  一种化合物的公式，其中R1和R2的定义如上所述，可用于治疗和改善选择的病症包括脑膜炎和输卵管炎、脓毒症、弥漫性血管内凝血、成人呼吸窘迫综合症、急性或慢性炎症、关节炎、胆管炎、结肠炎、脑炎、心内膜炎、肾小球肾炎、肝炎、心肌炎、胰腺炎、心包炎、再灌注损伤、血管炎、急性和迟发性过敏、移植排斥和移植物抗宿主病、自身免疫疾病，包括1型糖尿病和多发性硬化症、牙周病、间质性肺纤维化、肝硬化、全身性硬化、瘢痕形成、产生IL-1作为自分泌生长因子的肿瘤、消瘦症、阿尔茨海默病、振动伤害、抑郁症、动脉粥样硬化、哺乳动物，包括人类的骨质疏松症。
• Sulfonyl urea derivatives and their use in the control of interleukin-1
  申请人：Pfizer Inc

  公开号：US06166064A1

  公开（公告）日：2000-12-26

  A compound of formula (I) ##STR1## wherein R.sup.1 and R.sup.2 are as defined in the description, R.sup.2 being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including human.

  化合物式(I)的化合物，其中R.sup.1和R.sup.2如描述中所定义，R.sup.2是芳香族基团，可用于治疗和改善所选的疾病和情况，包括脑膜炎和输卵管炎、败血症性休克、弥漫性血管内凝血和/或成人呼吸窘迫综合症、急性或慢性炎症、关节炎、胆管炎、结肠炎、脑炎、心内膜炎、肾小球肾炎、肝炎、心肌炎、胰腺炎、心包炎、再灌注损伤、血管炎、急性和延迟型超敏反应、移植排斥反应和移植物抗宿主病、自身免疫性疾病包括1型糖尿病和多发性硬化症、牙周病、间质性肺纤维化、肝硬化、系统性硬化、瘢痕增生、产生IL-1的肿瘤作为自分泌生长因子、消瘦症、阿尔茨海默病、敲击伤、抑郁症、动脉粥样硬化、哺乳动物中的骨质疏松症，包括人类。
• 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives
  申请人：PFIZER INC.

  公开号：EP1270565A1

  公开（公告）日：2003-01-02

  The invention relates to a compound, 4-(1-hydroxy-1-methyl-ethyl)furan-2-sulfonamide, and its use as an intermediate in the preparation of a compound of the formula wherein R1 and R2 are as defined in the description, useful in the treatment and condition selected from the group consisting of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis (including cardiomyopathy, myocarditis and heart failure) and osteoporosis in a mammal, including a human.

  本发明涉及一种化合物，4-(1-羟基-1-甲基-乙基)呋喃-2-磺酰胺，及其在制备 式化合物中作为中间体的用途，其中 R1 和 R2 如描述中所定义。 其中 R1 和 R2 如描述中所定义，可用于治疗选自以下组别的疾病：脑膜炎和输卵管炎、脓毒性休克、弥散性血管内凝血和/或成人呼吸窘迫综合征、急性或慢性炎症、关节炎、胆管炎、结肠炎、脑炎、心内膜炎、肾小球肾炎、肝炎、心肌炎、胰腺炎、心包炎、再灌注损伤、血管炎、急性和迟发性超敏反应、移植物排斥和移植物抗宿主疾病、自身免疫性疾病（包括 1 型糖尿病和多发性硬化症）、牙周病、间质性肺纤维化、肝硬化、系统性硬化症、瘢痕疙瘩的形成、产生 IL-1 作为自分泌生长因子的肿瘤、恶病质、老年痴呆症、叩击伤、抑郁症、动脉粥样硬化（包括心肌病、心肌炎和心力衰竭）以及哺乳动物（包括人类）骨质疏松症。